{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:14:50Z","timestamp":1789456490831,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04172-x","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:30:19Z","timestamp":1788478219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A review of seamless phase I\/II trial designs towards oncology dose optimization with examples of clinical pharmacology considerations in early drug development"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5587-9962","authenticated-orcid":false,"given":"Yoko","family":"Franchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetayo","family":"Kasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Collette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"3","key":"4172_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpt.3361","volume":"116","author":"M Elmeliegy","year":"2024","unstructured":"Elmeliegy M et al (2024) Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology. Clin Pharmacol Ther 116(3):637\u2013646","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4172_CR2","doi-asserted-by":"publisher","first-page":"2149053","DOI":"10.1080\/19420862.2022.2149053","volume":"15","author":"S Mak","year":"2023","unstructured":"Mak S et al (2023) Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab. MAbs 15(1):2149053","journal-title":"MAbs"},{"key":"4172_CR3","unstructured":"US Food and Drug Administration Project Optimus [cited 2024 October 14]; Available from: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus"},{"issue":"3","key":"4172_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/19466315.2023.2166099","volume":"15","author":"O Marchenko","year":"2023","unstructured":"Marchenko O et al (2023) Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators. Stat Biopharm Res 15(3):697\u2013703","journal-title":"Stat Biopharm Res"},{"key":"4172_CR5","unstructured":"US Food and Drug Administration (2024) CDER Quantitative Medicine Center of Excellence (QM CoE). [cited 2024 October 28]; Available from: https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/cder-quantitative-medicine-center-excellence-qm-coe"},{"key":"4172_CR6","unstructured":"US Food and Drug Administration Oncology Dosing Tool Kit [cited 2024 October 28]; Available from: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/oncology-dosing-tool-kit"},{"key":"4172_CR7","doi-asserted-by":"crossref","unstructured":"Bittlinger M et al (2022) Ethical considerations for phase I trials in oncology. 40(30):3474\u20133488","DOI":"10.1200\/JCO.21.02125"},{"issue":"12","key":"4172_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41571-019-0296-z","volume":"16","author":"Editorial","year":"2019","unstructured":"Editorial (2019) Phase I trials: not all are made equal. Nat Reviews Clin Oncol 16(12):717\u2013717","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"4172_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0167-8140(92)90244-O","volume":"25","author":"H Suit","year":"1992","unstructured":"Suit H et al (1992) Clinical implications of heterogeneity of tumor response to radiation therapy. Radiother Oncol 25(4):251\u2013260","journal-title":"Radiother Oncol"},{"issue":"1","key":"4172_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/psp4.12479","volume":"9","author":"C Kuemmel","year":"2020","unstructured":"Kuemmel C et al (2020) Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation. CPT Pharmacometrics Syst Pharmacol 9(1):21\u201328","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"4172_CR11","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1038\/psp.2013.7","volume":"2","author":"E Manolis","year":"2013","unstructured":"Manolis E et al (2013) The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA\/EMA Modeling and Simulation Workshop. CPT Pharmacometrics Syst Pharmacol 2(2):e31","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4172_CR12","doi-asserted-by":"crossref","unstructured":"Friedman LM et al (2010) Fundamentals of clinical trials, vol 4. Springer","DOI":"10.1007\/978-1-4419-1586-3"},{"key":"4172_CR13","unstructured":"US Food and Drug Administration (2024) Guidance for industry: optimizing the dosage of human prescription. Drugs and biological products for the treatment of oncologic diseases"},{"key":"4172_CR14","doi-asserted-by":"crossref","unstructured":"Gallo P et al (2006) Adaptive designs in clinical drug development\u2013an Executive Summary of the PhRMA Working Group. J Biopharm Stat 16(3):275\u2013283; discussion 285\u2009\u2013\u200991, 293-8, 311\u20132","DOI":"10.1080\/10543400600614742"},{"issue":"5","key":"4172_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/2168479014523765","volume":"48","author":"O Sverdlov","year":"2014","unstructured":"Sverdlov O, Wong WK (2014) Novel Statistical Designs for Phase I\/II and Phase II Clinical Trials With Dose-Finding Objectives. Ther Innov Regul Sci 48(5):601\u2013612","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"4172_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00228-025-03930-7","volume":"82","author":"Y Franchetti","year":"2026","unstructured":"Franchetti Y (2026) A short review of dose-finding adaptive trial designs for clinical pharmacologists and non-statisticians in oncology. Eur J Clin Pharmacol 82(1):25","journal-title":"Eur J Clin Pharmacol"},{"issue":"31","key":"4172_CR17","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.2012.47.9949","volume":"31","author":"A Iasonos","year":"2013","unstructured":"Iasonos A, O\u2019Quigley J (2013) Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol 31(31):4014\u20134021","journal-title":"J Clin Oncol"},{"issue":"3","key":"4172_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/17407745231207085","volume":"21","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Zhou H, Liu S (2024) Statistical and practical considerations in planning and conduct of dose-optimization trials. Clin Trials 21(3):273\u2013286","journal-title":"Clin Trials"},{"key":"4172_CR19","doi-asserted-by":"crossref","unstructured":"Lin R et al (2020) BOIN12: Bayesian optimal interval phase I\/II trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis Oncol 4","DOI":"10.1200\/PO.20.00257"},{"issue":"29","key":"4172_CR20","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.1002\/sim.9591","volume":"41","author":"A Andrillon","year":"2022","unstructured":"Andrillon A et al (2022) Surv-CRM-12: A Bayesian phase I\/II survival CRM for right-censored toxicity endpoints with competing disease progression. Stat Med 41(29):5753\u20135766","journal-title":"Stat Med"},{"issue":"5","key":"4172_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/pst.1869","volume":"17","author":"B Guo","year":"2018","unstructured":"Guo B, Li D, Yuan Y (2018) SPIRIT: A seamless phase I\/II randomized design for immunotherapy trials. Pharm Stat 17(5):527\u2013540","journal-title":"Pharm Stat"},{"key":"4172_CR22","doi-asserted-by":"publisher","first-page":"106338","DOI":"10.1016\/j.cct.2021.106338","volume":"104","author":"L Jiang","year":"2021","unstructured":"Jiang L et al (2021) Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemp Clin Trials 104:106338","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"4172_CR23","first-page":"271","volume":"2","author":"J Liu","year":"2024","unstructured":"Liu J et al (2024) The Backfill i3\u2009+\u20093 Design for Dose-Finding Trials in Oncology. New Engl J Stat Data Sci 2(3):271\u2013283","journal-title":"New Engl J Stat Data Sci"},{"issue":"4","key":"4172_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1158\/1078-0432.CCR-23-2585","volume":"30","author":"Y Zhao","year":"2024","unstructured":"Zhao Y et al (2024) Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clin Cancer Res 30(4):673\u2013679","journal-title":"Clin Cancer Res"},{"key":"4172_CR25","doi-asserted-by":"publisher","first-page":"101329","DOI":"10.1016\/j.conctc.2024.101329","volume":"40","author":"JJZ Liao","year":"2024","unstructured":"Liao JJZ et al (2024) Three steps toward dose optimization for oncology dose finding. Contemp Clin Trials Commun 40:101329","journal-title":"Contemp Clin Trials Commun"},{"issue":"5","key":"4172_CR26","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/10543406.2014.920873","volume":"25","author":"NA Wages","year":"2015","unstructured":"Wages NA, Tait C (2015) Seamless Phase I\/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents. J Biopharm Stat 25(5):903\u2013920","journal-title":"J Biopharm Stat"},{"issue":"6","key":"4172_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/pst.1822","volume":"16","author":"S Yada","year":"2017","unstructured":"Yada S, Hamada C (2017) Adaptive phase I\/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle. Pharm Stat 16(6):433\u2013444","journal-title":"Pharm Stat"},{"issue":"1","key":"4172_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/10543406.2024.2364716","volume":"36","author":"S Yuan","year":"2026","unstructured":"Yuan S et al (2026) Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for seamless phase I-II trials in oncology. J Biopharm Stat 36(1):59\u201378","journal-title":"J Biopharm Stat"},{"key":"4172_CR29","unstructured":"Rowland MT, Thomas N (2011) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Wolters Kluwer Health\/Lippincott William & Wilkins, ed. Philadelphia, United States"},{"key":"4172_CR30","unstructured":"US Food and Drug Administration (2022) Guidance for industry: population pharmacokinetics. [cited 2026 July 5]; Available from: https:\/\/www.fda.gov\/media\/128793\/download"},{"issue":"3","key":"4172_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/bmjebm-2020-111573","volume":"27","author":"S Kluzek","year":"2022","unstructured":"Kluzek S, Dean B, Wartolowska KA (2022) Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med 27(3):153\u2013155","journal-title":"BMJ Evid Based Med"},{"issue":"3","key":"4172_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejca.2008.09.032","volume":"45","author":"A Bottomley","year":"2009","unstructured":"Bottomley A, Jones D, Claassens L (2009) Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer 45(3):347\u2013353","journal-title":"Eur J Cancer"},{"issue":"1","key":"4172_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12967-022-03849-y","volume":"21","author":"C Chen","year":"2023","unstructured":"Chen C et al (2023) Concept and application of the probability of pharmacological success (PoPS) as a decision tool in drug development: a position paper. J Transl Med 21(1):17","journal-title":"J Transl Med"},{"issue":"2","key":"4172_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/psp4.13271","volume":"14","author":"P Chotsiri","year":"2025","unstructured":"Chotsiri P et al (2025) Pharmacometric and statistical considerations for dose optimization. CPT Pharmacometrics Syst Pharmacol 14(2):279\u2013291","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"4172_CR35","first-page":"336","volume":"8","author":"I Zineh","year":"2019","unstructured":"Zineh I (2019) Quantitative Systems Pharmacology: A Regulatory Perspective on Translation. CPT: Pharmacometrics Syst Pharmacol 8(6):336\u2013339","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"4172_CR36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/psp4.13079","volume":"13","author":"W Gao","year":"2024","unstructured":"Gao W et al (2024) Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development. CPT Pharmacometrics Syst Pharmacol 13(5):691\u2013709","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4172_CR37","unstructured":"(2020) RETEVMO (selpercatinib) drug approval package. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213246Orig1s000TOC.cfm"},{"key":"4172_CR38","doi-asserted-by":"crossref","unstructured":"Turner DC et al (2023) Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making. (2163\u20138306 (Electronic)).","DOI":"10.1002\/psp4.12917"},{"key":"4172_CR39","unstructured":"Struemper HA-O et al (2025) Development of a joint tumor size-overall survival modeling and simulation framework supporting oncology development decision-making. LID\u2009\u2013\u200910.1002\/psp4.70002 [doi]. (2163\u20138306 (Electronic))."},{"key":"4172_CR40","unstructured":"Columbia University Irving Medical Center Augustus C. Long Health Sciences Library (2026) Narrative review methods and resources. [cited 2026 July 5, 2026]; Available from: https:\/\/library.cumc.columbia.edu\/kb\/narrative-review-methods-and-resources"},{"issue":"3","key":"4172_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0197-2456(01)00205-7","volume":"23","author":"TM Braun","year":"2002","unstructured":"Braun TM (2002) The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. Control Clin Trials 23(3):240\u2013256","journal-title":"Control Clin Trials"},{"issue":"3","key":"4172_CR42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.0006-341X.2004.00218.x","volume":"60","author":"PF Thall","year":"2004","unstructured":"Thall PF, Cook JD (2004) Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60(3):684\u2013693","journal-title":"Biometrics"},{"issue":"5","key":"4172_CR43","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/10543400600860394","volume":"16","author":"PF Thall","year":"2006","unstructured":"Thall PF, Cook JD, Estey EH (2006) Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations. J Biopharm Stat 16(5):623\u2013638","journal-title":"J Biopharm Stat"},{"issue":"3","key":"4172_CR44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1541-0420.2006.00534.x","volume":"62","author":"G Yin","year":"2006","unstructured":"Yin G, Li Y, Ji Y (2006) Bayesian dose-finding in phase I\/II clinical trials using toxicity and efficacy odds ratios. Biometrics 62(3):777\u2013784","journal-title":"Biometrics"},{"issue":"21","key":"4172_CR45","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1002\/sim.8292","volume":"38","author":"MI Alam","year":"2019","unstructured":"Alam MI, Coad DS, Bogacka B (2019) Combined criteria for dose optimisation in early phase clinical trials. Stat Med 38(21):4172\u20134188","journal-title":"Stat Med"},{"issue":"2","key":"4172_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10543406.2018.1535496","volume":"29","author":"D Yan","year":"2019","unstructured":"Yan D, Wages NA, Dressler EV (2019) Improved adaptive randomization strategies for a seamless Phase I\/II dose-finding design. J Biopharm Stat 29(2):333\u2013347","journal-title":"J Biopharm Stat"},{"issue":"28","key":"4172_CR47","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1002\/sim.8361","volume":"38","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Lee JJ, Yuan Y (2019) A utility-based Bayesian optimal interval (U-BOIN) phase I\/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med 38(28):5299\u20135316","journal-title":"Stat Med"},{"issue":"3","key":"4172_CR48","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/biom.13347","volume":"77","author":"Y Zhang","year":"2021","unstructured":"Zhang Y et al (2021) A Bayesian adaptive phase I\/II clinical trial design with late-onset competing risk outcomes. Biometrics 77(3):796\u2013808","journal-title":"Biometrics"},{"issue":"7","key":"4172_CR49","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/sim.9265","volume":"41","author":"B Guo","year":"2022","unstructured":"Guo B, Zang Y (2022) BIPSE: A biomarker-based phase I\/II design for immunotherapy trials with progression-free survival endpoint. Stat Med 41(7):1205\u20131224","journal-title":"Stat Med"},{"issue":"6","key":"4172_CR50","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1177\/09622802221079353","volume":"31","author":"H Jin","year":"2022","unstructured":"Jin H, Yin G (2022) CFO: Calibration-free odds design for phase I\/II clinical trials. Stat Methods Med Res 31(6):1051\u20131066","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"4172_CR51","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/pst.2301","volume":"22","author":"PF Thall","year":"2023","unstructured":"Thall PF, Zang Y, Yuan Y (2023) Generalized phase I-II designs to increase long term therapeutic success rate. Pharm Stat 22(4):692\u2013706","journal-title":"Pharm Stat"},{"key":"4172_CR52","doi-asserted-by":"publisher","first-page":"107139","DOI":"10.1016\/j.cct.2023.107139","volume":"127","author":"Y Qiu","year":"2023","unstructured":"Qiu Y et al (2023) Modified isotonic regression based phase I\/II clinical trial design identifying optimal biological dose. Contemp Clin Trials 127:107139","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"4172_CR53","doi-asserted-by":"publisher","first-page":"e73060","DOI":"10.1371\/journal.pone.0073060","volume":"8","author":"H Pan","year":"2013","unstructured":"Pan H et al (2013) A novel Bayesian seamless phase I\/II design. PLoS ONE 8(9):e73060","journal-title":"PLoS ONE"},{"issue":"21","key":"4172_CR54","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1002\/sim.9080","volume":"40","author":"L Biard","year":"2021","unstructured":"Biard L, Lee SM, Cheng B (2021) Seamless phase I\/II design for novel anticancer agents with competing disease progression. Stat Med 40(21):4568\u20134581","journal-title":"Stat Med"},{"issue":"26","key":"4172_CR55","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1002\/sim.7428","volume":"36","author":"R Lin","year":"2017","unstructured":"Lin R, Yin G (2017) STEIN: A simple toxicity and efficacy interval design for seamless phase I\/II clinical trials. Stat Med 36(26):4106\u20134120","journal-title":"Stat Med"},{"issue":"9","key":"4172_CR56","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/ijc.34203","volume":"151","author":"JJZ Liao","year":"2022","unstructured":"Liao JJZ et al (2022) A hybrid design for dose-finding oncology clinical trials. Int J Cancer 151(9):1602\u20131610","journal-title":"Int J Cancer"},{"key":"4172_CR57","doi-asserted-by":"crossref","unstructured":"Ji Y, S.-J.J.J.o.C O, Wang (2013) Modified toxicity probability interval design: a safer and more reliable method than the 3\u2009+\u20093 design for practical phase I trials. 31(14):1785\u20131791","DOI":"10.1200\/JCO.2012.45.7903"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04172-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04172-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04172-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:42Z","timestamp":1789454862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04172-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4172"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04172-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of GSK and own shares\/stocks in GSK. P.N. owns shares\/stocks in Haleon as well.","order":3,"name":"Ethics","label":"Financial disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"243"}}